- Home
- AMSF vs CRGX Comparison
AMSF vs CRGX Comparison
Compare AMSF & CRGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMSF
- CRGX
- Stock Information
- Founded
- AMSF 1985
- CRGX 2021
- Country
- AMSF United States
- CRGX United States
- Employees
- AMSF N/A
- CRGX N/A
- Industry
- AMSF Accident &Health Insurance
- CRGX
- Sector
- AMSF Finance
- CRGX
- Exchange
- AMSF Nasdaq
- CRGX Nasdaq
- Market Cap
- AMSF 869.6M
- CRGX 190.0M
- IPO Year
- AMSF 2005
- CRGX 2023
- Fundamental
- Price
- AMSF $44.16
- CRGX $4.59
- Analyst Decision
- AMSF Buy
- CRGX Hold
- Analyst Count
- AMSF 2
- CRGX 7
- Target Price
- AMSF $59.50
- CRGX $5.33
- AVG Volume (30 Days)
- AMSF 143.6K
- CRGX 1.9M
- Earning Date
- AMSF 07-24-2025
- CRGX 08-11-2025
- Dividend Yield
- AMSF 10.56%
- CRGX N/A
- EPS Growth
- AMSF N/A
- CRGX N/A
- EPS
- AMSF 2.48
- CRGX N/A
- Revenue
- AMSF $301,216,000.00
- CRGX N/A
- Revenue This Year
- AMSF $1.69
- CRGX $57.81
- Revenue Next Year
- AMSF $6.54
- CRGX N/A
- P/E Ratio
- AMSF $17.81
- CRGX N/A
- Revenue Growth
- AMSF N/A
- CRGX N/A
- 52 Week Low
- AMSF $42.48
- CRGX $3.00
- 52 Week High
- AMSF $60.24
- CRGX $25.45
- Technical
- Relative Strength Index (RSI)
- AMSF 47.66
- CRGX 61.56
- Support Level
- AMSF $42.80
- CRGX $4.32
- Resistance Level
- AMSF $44.19
- CRGX $4.63
- Average True Range (ATR)
- AMSF 0.91
- CRGX 0.16
- MACD
- AMSF 0.14
- CRGX 0.04
- Stochastic Oscillator
- AMSF 81.55
- CRGX 76.44
About AMSF AMERISAFE Inc.
AMERISAFE Inc is a specialty provider of workers' compensation insurance focused on small to mid-sized employers engaged in hazardous industries, principally construction, trucking, logging and lumber, agriculture, manufacturing, maritime, and telecommunications. The company generates a majority of its revenue in the form of premiums.
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platforms, and manufacturing are designed to directly address the limitations of approved chimeric antigen receptor (CAR) T-cell therapies. Its product includes CRG-023, an investigational tri-specific CAR T designed to address several known causes of relapse associated with existing CAR T-cell therapies such as loss of tumor antigen expression, loss of co-stimulation (e.g., via CD58/CD2 signaling) and T cell exhaustion. CRG-023 is designed to target the B-cell lineage antigens (CD19, CD20, CD22) via tri-cistronic expression of three distinct CARs from a single lentiviral vector.